ArticleAdvanced healthcare materials2026
Chemokine-Guided Biomimetic Mn/Ce Nanozymes for Immunomodulation and Cardioprotection in Doxorubicin-Induced Cardiomyopathy.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Doxorubicin-induced cardiomyopathy (DIC) remains a major dose-limiting complication of anthracycline chemotherapy, with no effective targeted therapies available. Emerging evidence suggests that maladaptive inflammation, driven by aberrant monocyte recruitment, synergizes with oxidative stress to exacerbate myocardial injury. In particular, the CCL2-CCR2 chemokine axis plays a pivotal role in inflammatory cell trafficking and disease progression. An engineered biomimetic nanozyme, termed CCR2-MM@Mn/CeZ, is developed for inflammation-targeted cardioprotection. This platform comprises a Mn/Ce co-doped ZIF-8 nanozyme core with intrinsic antioxidant activity, cloaked by macrophage membranes (MM) overexpressing CCR2. This design enables selective homing to inflamed myocardium via CCL2 recognition, prolonged cardiac retention, and simultaneous modulation of inflammatory and oxidative microenvironments. In a DIC mouse model, CCR2-MM@Mn/CeZ significantly enhances myocardial accumulation, suppresses pro-inflammatory macrophage infiltration, promotes M2 polarization, and reduces intracellular reactive oxygen species. Transcriptomic analysis further reveals coordinated downregulation of inflammatory pathways and restoration of redox and metabolic homeostasis. Meanwhile, Mn
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.